Effect of sulfasalazine on digoxin bioavailability.
Low levels of digoxin were noted in a patient receiving digoxin and sulfasalazine (SSA). Discontinuation of SSA resulted in a significant increase in serum digoxin levels. To determine whether or not SSA consistently interfered with the therapeutic effect of digoxin, both drugs were administered to 10 normal subjects in a crossover study. Each received 2 doses of digoxin (0.5 mg, elixir): one dose given alone, and a second dose after 6 days of treatment with SSA. When digoxin was given with SSA, the average area under the serum digoxin curve fell from the control value of 8.79 ng-hr-ml(-1) to 6.66 ng-hr-ml(-1) (p less than 0.05), fell and total urinary excretion decreased from 278 mcg/10 days to 228 mcg/10 days (p less than 0.025). These changes suggest interference with the bioavailability of digoxin by SSA. Studies were conducted to determine whether SSA inhibited digoxin absorption by physically absorbing the glycoside from solution. In vitro tests failed to reveal any significant adsorptive properties for SSA.
D000042:Absorption; D000328:Adult; D001682:Biological Availability; D004077:Digoxin / Q000032:analysis / Q000378:metabolism* / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D007700:Kinetics; D008297:Male; D012460:Sulfasalazine / Q000494:pharmacology*; D013997:Time Factors
D012460:Sulfasalazine; D004077:Digoxin